The Endeavours in RAS Inhibition - the Past, Present, and Future.

Abstract excerpt

KRAS mutations are known to be the most recurrent gain-of-function changes instigated in patients with cancer. The RAS gene family is often mutated in most of the human cancers, and the pursuit of inhibitors that bind to mutant RAS continues as a foremost target. RAS is a small GTPase that controls numerous cellular functions, including cell proliferation, growth, survival, and gene expression. RAS is hence...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Drug Discovery
• Mutation
• Neoplasms
• ras Proteins